{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:16:41Z","timestamp":1793261801819,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.diagmicrobio.2018.06.002","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T08:14:19Z","timestamp":1529396059000},"page":"250-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin, and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution"],"prefix":"10.1016","volume":"92","author":[{"given":"Cindy","family":"Wolfe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris M.","family":"Pillar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean L.","family":"Shinabarger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiz A.","family":"Boulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0005","series-title":"2015 Medicines in Development for Cancer","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0010","series-title":"Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0015","series-title":"Antibiotic resistance threats in the United States 2013","first-page":"1","year":"2013"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/antibiotics4030267","volume":"4","author":"Baines","year":"2015","journal-title":"Antibiotics"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0025","series-title":"CLSI document M11-A8","article-title":"Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2012"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0030","series-title":"CLSI document M100-S27","article-title":"Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Seventh Informational Supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0035","series-title":"Clinical development success rates 2006\u20132015","year":"2016"},{"issue":"Suppl. 2","key":"10.1016\/j.diagmicrobio.2018.06.002_bb0040","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/cid\/cis499","volume":"55","author":"Crook","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0045","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/jac\/dkt013","volume":"68","author":"Debast","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0050","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1128\/AAC.00625-11","volume":"55","author":"Goldstein","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ja.2015.4","volume":"68","author":"Iscla","year":"2015","journal-title":"J Antibiot"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0060","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1021\/jm5016846","volume":"58","author":"Jarrad","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0065","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/AAC.46.6.1647-1650.2002","volume":"46","author":"Pelaez","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13756-017-0214-z","volume":"6","author":"Putsathit","year":"2017","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0075","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ja.2016.45","volume":"69","author":"Rao","year":"2016","journal-title":"J Antibiot"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0080","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/eri.10.28","volume":"8","author":"Shah","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0085","series-title":"Tackling drug-resistant infections globally: final report and recommendations","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2018.06.002_bb0090","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/CMR.18.2.247-263.2005","volume":"18","author":"Voth","year":"2005","journal-title":"Clin Microbiol Rev"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318301883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318301883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T07:47:25Z","timestamp":1538466445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889318301883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0732889318301883"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.06.002","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin, and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}